SK Capital completed the acquisition of Apotex.

SK Capital, a private investment firm with a disciplined focus on the specialty materials, specialty chemicals, and pharmaceuticals sectors, completed the acquisition of Apotex, a Canadian, global pharmaceutical company. Financial terms were not disclosed. “Apotex is a dynamic, entrepreneurial company with a strong track record of success, underpinned by its diversified product portfolio, robust pipeline of new launches and iconic brand. We feel incredibly privileged to have the opportunity to support Apotex with our deep experience in the pharmaceutical sector as it continues to research, develop and produce safe and affordable medicines for patients in Canada, the United States and around the world,” Aaron Davenport, SK Capital Managing Director.